resiquimod has been researched along with Benign Neoplasms in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (69.23) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Guo, W; Jia, D; Li, G; Li, J; Liu, R; Lu, X; Lu, Y; Lv, M; Wang, F; Wang, R; Wei, J; Yuan, F; Zhu, W | 1 |
| Abbasi, A; Burt, AJ; Davaritouchaee, M; Hendricksen, AT; Mancini, RJ; Nielsen, AE; Opp, LK; Pulukuri, AJ; Ryan, AT | 1 |
| Bahmani, B; Bui, JD; DeTeresa, E; Fang, RH; Gao, W; Gong, H; Haushalter, KJ; Luk, BT; Previti, M; Zhang, J; Zhang, L; Zhou, J | 1 |
| Cao, G; Geng, J; Li, D; Li, H; Li, Y; Song, Q; Wang, B; Wang, Y; Zhang, G; Zhang, Y | 1 |
| Bayik, D; Klinman, DM; Tross, D | 1 |
| Alam, MM; Meyer, TJ; Oppenheim, JJ; Trivett, A | 1 |
| Allémann, E; Bourquin, C; Delie, F; Hocevar, S; Mottas, I; Thauvin, C; Widmer, J | 1 |
| Ahmed, MS; Arlauckas, SP; Cuccarese, MF; Garris, CS; Kohler, RH; Li, R; Pittet, MJ; Rodell, CB; Weissleder, R | 1 |
| Riedmann, EM | 1 |
| Klier, U; Linnebacher, M; Maletzki, C; Stier, S | 1 |
| Caisová, V; Chmelař, J; Glaserová, S; Husníková, H; Jochmanová, I; Kopecký, J; Krejčová, G; Kumžáková, Z; Paďouková, L; Vácová, N; Vieru, A; Wolf, KI; Ženka, J | 1 |
| Cohen, PA; Dang, Y; Disis, ML; Dominguez, AL; Gendler, SJ; Gorman, JE; McCurry, DB; Mihalik, LA; Pathangey, G; Pathangey, LB | 1 |
| Amer, A; Butchar, JP; Byrd, JC; Carson, WE; Chemudupati, M; Guenterberg, KD; Jarjoura, D; Justiniano, SE; Kanneganti, TD; Kondadasula, SV; Marsh, CB; Mehta, P; Mo, X; Muthusamy, N; Tridandapani, S | 1 |
13 other study(ies) available for resiquimod and Benign Neoplasms
| Article | Year |
|---|---|
Targeted co-delivery of resiquimod and a SIRPα variant by liposomes to activate macrophage immune responses for tumor immunotherapy.
Topics: CD47 Antigen; Humans; Immunotherapy; Liposomes; Macrophages; Mannose; Neoplasms; Phagocytosis; Tumor Microenvironment | 2023 |
Comparing the immunogenicity of glycosidase-directed resiquimod prodrugs mediated by cancer cell metabolism.
Topics: Adjuvants, Immunologic; Animals; Cells, Cultured; Glycoside Hydrolases; Imidazoles; Macrophages; Mice; Neoplasms; Prodrugs | 2020 |
Intratumoral immunotherapy using platelet-cloaked nanoparticles enhances antitumor immunity in solid tumors.
Topics: Animals; Blood Platelets; Breast Neoplasms; Cell Line, Tumor; Cell Membrane; Cells, Cultured; Female; HT29 Cells; Humans; Imidazoles; Immunotherapy; Lung Neoplasms; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Treatment Outcome; Tumor Microenvironment | 2021 |
Reinforcing the Combinational Immuno-Oncotherapy of Switching "Cold" Tumor to "Hot" by Responsive Penetrating Nanogels.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Animals; Antineoplastic Agents; B7-H1 Antigen; Catechin; Cell Line, Tumor; Dendritic Cells; Drug Carriers; Drug Liberation; Female; Hyaluronic Acid; Imidazoles; Immunomodulation; Mice, Inbred C57BL; Nanogels; Neoplasms; T-Lymphocytes, Cytotoxic; T-Lymphocytes, Regulatory; Tumor Microenvironment | 2021 |
Factors Influencing the Differentiation of Human Monocytic Myeloid-Derived Suppressor Cells Into Inflammatory Macrophages.
Topics: Cell Differentiation; Cells, Cultured; Cytokines; Cytotoxicity, Immunologic; Gene Expression Profiling; Humans; Imidazoles; Immune Tolerance; Immunotherapy; Inflammation; Inflammation Mediators; Monocytes; Myeloid-Derived Suppressor Cells; Neoplasms; NF-kappa B; STAT4 Transcription Factor; Tumor Escape | 2018 |
HMGN1 and R848 Synergistically Activate Dendritic Cells Using Multiple Signaling Pathways.
Topics: Animals; Cell Differentiation; Cytokines; Dendritic Cells; Drug Synergism; Female; Gene Expression Regulation; HMGN1 Protein; Humans; Imidazoles; Immunotherapy; Mice; Mice, Inbred C57BL; Monocytes; Neoplasms; Recombinant Proteins; Signal Transduction; Th1 Cells; Transcription Factors | 2018 |
Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study.
Topics: Adjuvants, Immunologic; Animals; Cell Line; Cell Survival; Drug Carriers; Drug Compounding; Imidazoles; Immunotherapy; Macrophage Activation; Macrophages; Mice; Mice, Inbred C57BL; Nanoparticles; Neoplasms; Particle Size; Polyesters; Primary Cell Culture | 2019 |
TLR7/8-agonist-loaded nanoparticles promote the polarization of tumour-associated macrophages to enhance cancer immunotherapy.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Humans; Imidazoles; Immunotherapy; Macrophages; Mice; Nanoparticles; Neoplasms; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Microenvironment | 2018 |
CDX-1401 combined with TLR agonist: positive phase 1 results.
Topics: Adjuvants, Immunologic; Cancer Vaccines; Clinical Trials, Phase I as Topic; Humans; Imidazoles; Immunotherapy; Neoplasms | 2012 |
Combinations of TLR ligands: a promising approach in cancer immunotherapy.
Topics: Animals; Cell Line, Tumor; Disease Models, Animal; Female; Humans; Imidazoles; Immunomodulation; Immunotherapy; Ligands; Lymphocytes; Mice; Neoplasms; Paclitaxel; Poly I-C; Toll-Like Receptors; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |
Innate immunity based cancer immunotherapy: B16-F10 murine melanoma model.
Topics: Animals; Cytokines; Disease Models, Animal; Female; Imidazoles; Immunity, Innate; Immunotherapy; Ligands; Mannans; Melanoma, Experimental; Mice; Neoplasms; Neutrophil Infiltration; Neutrophils; Phagocytosis; Poly I-C; Respiratory Burst; Toll-Like Receptors | 2016 |
Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.
Topics: Antigens, Neoplasm; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cell Proliferation; Cells, Cultured; Cross-Priming; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Imidazoles; Immunity, Innate; Immunotherapy, Adoptive; Interferon-gamma; Interleukin-2; Interleukin-7; Leukocytes, Mononuclear; Lipopolysaccharides; Lymphocyte Activation; Mucin-1; Neoplasms; Peptides; Receptor, ErbB-2; T-Lymphocytes, Regulatory | 2017 |
Reciprocal regulation of activating and inhibitory Fc{gamma} receptors by TLR7/8 activation: implications for tumor immunotherapy.
Topics: Animals; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Agents; Cytokines; Humans; Imidazoles; Immunologic Factors; Immunotherapy; Macrophages; Mice; Mice, Inbred C57BL; Mice, Knockout; Neoplasms; Receptors, IgG; Toll-Like Receptor 7; Toll-Like Receptor 8; Tumor Cells, Cultured | 2010 |